ResMed has officially joined the ranks of the ASX’s 50 top companies.
The post Here’s why the ResMed (ASX:RMD) share price is in the green today appeared first on The Motley Fool Australia. –
The ResMed Inc. (ASX: RMD) share price is in the green today after it was boosted into the S&P/ASX 50 Index (ASX: XFL).
The respiratory medical device company focused on the treatment of sleep-apnoea is now officially one of ASX’s largest companies, and the market is seemingly pleased with its recognition.
Right now, the ResMed share price is $39.55, 0.64% higher than its previous close.
Let’s take a closer look at ResMed’s new spot among the exchange’s top dogs.
ResMed joins the ASX’s top 50
The ResMed share price is gaining today as the company moves in with ASX’s big wigs.
S&P Dow Jones Index’s quarterly rebalance of the S&P/ASX indices dropped after Friday’s close.
Those interested in how other S&P/ASX index’s faired through the rebalance can find The Motley Fool Australia’s in-depth report on all the changes here.
It’s no wonder the healthcare company has wiggled its way into a higher class. The ResMed share price has gained an impressive 64% over the last 6 months.
For comparison, the S&P/ASX 200 Index (ASX: XJO) increased just 11% in the same time frame.
ResMed’s stock isn’t only gaining today, it’s also flying off the shelf.
An average month sees 906,863 of the company’s shares swap hands. Today, more than 1.4 million of ResMed’s securities have been traded. That represents more than $55 million worth of ResMed stock.
ResMed share price snapshot
The ResMed share price has gained 43% year to date. It has also increased 66% since this time last year.
The company has a market capitalisation of around $57 billion.
Should you invest $1,000 in ResMed right now?
Before you consider ResMed, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended A2 Milk and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.